TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21180008

Group type: EXPERIMENTAL
Intervention: Oxalate desensitizer (OX) with Optibond FL (OBFL)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Oxalate desensitizer (OX) with Excite (EX)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Oxalate desensitizer (OX) with One-Step Plus (OS)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Oxalate desensitizer (OX) with Adper Scotchbond Multi‐Purpose (SBMP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oxalate desensitizer (OX) without adhesive (negative control)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control groups with Adper Scotchbond Multi‐Purpose (SBMP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control groups with Optibond FL (OBFL)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control groups with One-Step Plus (OS)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control groups with Excite (EX)
Number of subjects: 126
Study: 18166119

Group type: EXPERIMENTAL
Intervention: Yoga training for 6 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Routine physical training exercise for 6 months (Control)
Number of subjects: 51
Study: 15906066

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (400 mcg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravitreal vancomycin (0.2 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 11882229

Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg.kg-1 at induction followed by continuous infusion of 3 mg.kg-1 over 24 h (preketoprofen group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg.kg-1 after surgery followed by continuous infusion of 3 mg.kg-1 over 24 h (postketoprofen group)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Normal saline (placebo group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Ketoprofen (both groups)
Number of subjects: 109
Study: 9814468

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy with dose titration starting at 0.8 IU/day subcutaneously (0.4 IU/day if hypertensive or glucose tolerance impaired)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy with dose titration
Number of subjects: 71
Study: 8695002

Group type: EXPERIMENTAL
Intervention: Amalgambond adhesive agent
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (untreated sensitive teeth)
Number of subjects: 19
Study: 2777580

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 gram)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 878122

Group type: EXPERIMENTAL
Intervention: Resection via perineal urethrostomy (Group B)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Resection via the entire urethra (Group C)
Number of subjects: 173
Study: 31289439

Group type: EXPERIMENTAL
Intervention: Flipping education program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional patient education
Number of subjects: 60
Study: 28167237

Group type: EXPERIMENTAL
Intervention: High Dose (4000IU/d) vitamin D3
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: High Dose (4000IU/d) vitamin D3 among those with insufficient 25(OH)D (<75nmol/L) at baseline
Number of subjects: 82
Study: 25714615

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg alternate days, 12 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 46
Study: 23505005

Group type: EXPERIMENTAL
Intervention: Perceptual pattern separation in older adults
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Conceptual pattern separation in older adults
Number of subjects: 2

Group type: COMPARATOR
Intervention: Perceptual pattern separation in young adults
Number of subjects: 2

Group type: COMPARATOR
Intervention: Working memory, attention, or visual processing
Number of subjects: 2
Study: 21685641

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy (VRET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy using head-mounted display (HMD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy using computer automatic virtual environment (CAVE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 18951454

Group type: EXPERIMENTAL
Intervention: Motivation intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Relaxation intervention
Number of subjects: 38
Study: 16859143

Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure ventilation (BiPAP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Extubation when awake (Group A)
Number of subjects: 40
Study: 15228844

Group type: EXPERIMENTAL
Intervention: Cyclosporin-A in combination with methotrexate
Number of subjects: 63
Study: 11471481

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care management by pharmacists in the intervention group.
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Standard care in the control group.
Number of subjects: 1054
Study: 9429994

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg (multiple doses)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Acetaminophen 300 mg plus codeine phosphate 30 mg (control)
Number of subjects: 83
Study: 8504531

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (2.8 micrograms of sodium selenite per kilogram of body weight per day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 27
Study: 3479296

Group type: EXPERIMENTAL
Intervention: Oral solution of 300 mg ofloxacin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Tablet form of 300 mg ofloxacin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both oral solution and tablet form of 300 mg ofloxacin
Number of subjects: 13
Study: 31954679

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral and tricuspid valve repair (TMTVR)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Isolated transcatheter mitral valve repair (TMVR)
Number of subjects: 228
Study: 29309282

Group type: EXPERIMENTAL
Intervention: Lung ultrasound examinations and ultrasound-guided recruitment maneuver
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lung ultrasound examinations only (control group)
Number of subjects: 120
Study: 27451327

Group type: EXPERIMENTAL
Intervention: 2mg E4
Number of subjects: 49

Group type: COMPARATOR
Intervention: 2mg E2V
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 10mg E4
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 20mg E4
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 40mg E4
Number of subjects: 49
Study: 24743712

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/d
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 600 mg/d
Number of subjects: 21

Group type: COMPARATOR
Intervention: Quetiapine XR 300 mg/d vs 600 mg/d
Number of subjects: 21
Study: 24202220

Group type: EXPERIMENTAL
Intervention: Solid pectin‐based skin barrier
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gauze
Number of subjects: 0
Study: 20453723

Group type: EXPERIMENTAL
Intervention: Surgical treatment (standard decompressive laminectomy)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Nonoperative care
Number of subjects: 654
Study: 18476982

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg q.d. as add-on to metformin therapy or as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg q.d. as monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16669963

Group type: EXPERIMENTAL
Intervention: Bisacodyl, 10 mg once daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bisacodyl and Placebo
Number of subjects: 55
Study: 15568942

Group type: EXPERIMENTAL
Intervention: Respiration of 100% oxygen for 6 min
Number of subjects: 2

Group type: COMPARATOR
Intervention: Young healthy subject
Number of subjects: 2

Group type: COMPARATOR
Intervention: Patient suffering from dry age-related macular degeneration
Number of subjects: 2
Study: 11406322

Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9008376

Group type: EXPERIMENTAL
Intervention: Inducing empathy for a young woman with AIDS
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Inducing empathy for a homeless man
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Inducing empathy toward a convicted murderer
Number of subjects: 3
Study: 8477272

Group type: EXPERIMENTAL
Intervention: Bulimic subjects
Number of subjects: 24

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 24
Study: 3459738

Group type: EXPERIMENTAL
Intervention: Oral prophylaxis immediately
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral prophylaxis 6 weeks after baseline
Number of subjects: 200
Study: 30956141

Group type: EXPERIMENTAL
Intervention: Attention-based training (ABT) program, four sessions (4 h/session) over 7 weeks, practice target of 20 min twice-daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention-based training (ABT) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study: 29468642

Group type: EXPERIMENTAL
Intervention: 8 ml ropivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 8 ml isotonic saline
Number of subjects: 20
Study: 26511535

Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 15244

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 15244

Group type: EXPERIMENTAL
Intervention: DBP ≥ 90 mmHg
Number of subjects: 15244

Group type: EXPERIMENTAL
Intervention: DBP < 70 mmHg
Number of subjects: 15244

Group type: EXPERIMENTAL
Intervention: Systolic BP ≥ 150 mmHg
Number of subjects: 15244

Group type: EXPERIMENTAL
Intervention: Systolic BP < 130 mmHg
Number of subjects: 15244

Group type: EXPERIMENTAL
Intervention: DBP strata ≥ 150/90 mmHg
Number of subjects: 15244

Group type: EXPERIMENTAL
Intervention: DBP strata < 130/70 mmHg
Number of subjects: 15244
Study: 23774010

Group type: EXPERIMENTAL
Intervention: Sidman avoidance procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Operant variability procedure
Number of subjects: 0
Study: 22854412

Group type: EXPERIMENTAL
Intervention: High-antioxidant diet (5 servings of vegetables and 2 servings of fruit daily; n = 46)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Low-antioxidant diet (≤2 servings of vegetables and 1 serving of fruit daily; n = 91)
Number of subjects: 137
Study: 20616619

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Exenatide
Number of subjects: 38

Group type: COMPARATOR
Intervention: Vildagliptin
Number of subjects: 38
Study: 17610650

Group type: EXPERIMENTAL
Intervention: Involved skin of DM patients
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Non-involved skin of DM patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study: 15919283

Group type: EXPERIMENTAL
Intervention: Low-dose anticoagulation (target INR range 1.8 to 2.8 for aortic valve replacement and 2.5 to 3.5 for mitral or double valve replacement)
Number of subjects: 1818

Group type: COMPARATOR
Intervention: Conventional-dose anticoagulation (target INR range 2.5 to 4.5 for all heart valve prostheses)
Number of subjects: 1818
Study: 12033981

Group type: EXPERIMENTAL
Intervention: PureVision lenses (Bausch & Lomb)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Focus Night & Day lenses (CIBA Vision)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both lenses
Number of subjects: 30
Study: 9818597

Group type: EXPERIMENTAL
Intervention: Combined topical-intracameral anesthesia (1% lidocaine)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Topical lidocaine (2% lidocaine hydrochloride) alone
Number of subjects: 162
Study: 7696065

Group type: EXPERIMENTAL
Intervention: 1 MAC of sevoflurane
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 MAC of sevoflurane
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 MAC of isoflurane
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 MAC of isoflurane
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 MAC of halothane
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 MAC of halothane
Number of subjects: 36
Study: 2796753

Group type: EXPERIMENTAL
Intervention: Decision support system using decision tables
Number of subjects: 0
Study: 787913

Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 179

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 179
Study: 31599811

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 44
Study: 31002578

Group type: COMPARATOR
Intervention: IV carboplatin
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: IP carboplatin
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: IP cisplatin
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 1560
Study: 27465823

Group type: COMPARATOR
Intervention: Local anaesthetic alone (Arm A)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Local anaesthetic plus corticosteroid (Arms B and C)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Local anaesthetic plus corticosteroid with a large volume of normal saline (Arm C)
Number of subjects: 201
Study: 24849736

Group type: EXPERIMENTAL
Intervention: Daily supplementation with 26 vitamins and minerals tablet
Number of subjects: 3318

Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 3318
Study: 23873823

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) 300 μg every 2 weeks starting on Day 28 after HCT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) plus intravenous (i.v.) iron 200 mg on Days 28, 42, and 56
Number of subjects: 72

Group type: COMPARATOR
Intervention: No darbepoetin alfa (Arm 1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) plus intravenous (i.v.) iron
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) administration
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) iron administration
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High baseline hemoglobin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low baseline creatinine
Number of subjects: 72
Study: 21726411

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 371

Group type: COMPARATOR
Intervention: Metformin/Placebo
Number of subjects: 371

Group type: COMPARATOR
Intervention: Insulin Aspart/NPH Insulin with Metformin/Placebo
Number of subjects: 371

Group type: COMPARATOR
Intervention: Insulin Aspart/NPH Insulin with Rosiglitazone/Placebo
Number of subjects: 371
Study: 19562990

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels measured by Kryptor assay
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels measured by VIDAS assay
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) at a threshold of 0.5 ng/mL
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) thresholds
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels in severe sepsis and MOD group
Number of subjects: 56
Study: 17206671

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 1 mg/g (1 g ointment twice a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus
Number of subjects: 19
Study: 15502061

Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM) - 250 microg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted femoral nerve block (FNB) - 40 mL of 0.5% ropivacaine, 5 microg/mL of epinephrine, and 75 microg of clonidine
Number of subjects: 41
Study: 11392450

Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Population PK/PD models
Number of subjects: 640
Study: 9785066

Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia combined with intercostal blockade (T7-T11) using 0.45% bupivacaine and 0.6% phenol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia alone
Number of subjects: 37
Study: 8162986

Group type: EXPERIMENTAL
Intervention: ICI-204,219 (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3348735

Group type: EXPERIMENTAL
Intervention: Vein bypass (including in situ and reversed saphenous vein)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Prosthetic bypass
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Vein bypass
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: In situ and reversed saphenous vein bypasses
Number of subjects: 596
Study: 31721596

Group type: EXPERIMENTAL
Intervention: Nicotine-session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine-free-session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stop-session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine-session and Nicotine-free-session
Number of subjects: 0
Study: 31158295

Group type: EXPERIMENTAL
Intervention: Facilitated reminiscence
Number of subjects: 13

Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 13
Study: 28646809

Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model (FDM) treatment
Number of subjects: 77

Group type: COMPARATOR
Intervention: NDMG treatment (control)
Number of subjects: 77
Study: 25844684

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol
Number of subjects: 720

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 720
Study: 23965206

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg bolus before incision, followed by 15 mg/kg continuous infusion until skin closure)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 21075773

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD) only therapy
Number of subjects: 704
Study: 19841361

Group type: EXPERIMENTAL
Intervention: Artificial pancreas (n = 17)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sliding scale method (n = 13)
Number of subjects: 30
Study: 16415310

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus clonidine (Group R)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal saline (Group S)
Number of subjects: 23
Study: 15231441

Group type: EXPERIMENTAL
Intervention: Gulf War veterans with PTSD
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (healthy, nondeployed veterans)
Number of subjects: 19
Study: 10911769

Group type: EXPERIMENTAL
Intervention: Low-fat diet enriched in medium-chain triacylglycerol (TAG)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Standardized lipid-enriched test meal
Number of subjects: 2
Study: 9118189

Group type: EXPERIMENTAL
Intervention: 1.77% KAl(SO4) toothpaste
Number of subjects: 2087

Group type: COMPARATOR
Intervention: 0.83% NaFPO3 toothpaste
Number of subjects: 2087
Study: 8440429

Group type: EXPERIMENTAL
Intervention: Microwave coagulation (non-contact method)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polidocanol 1% + adrenaline 1:10,000 injection
Number of subjects: 40
Study: 3734514

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (200 mg t.i.d.)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Raynaud's patients
Number of subjects: 39
Study: 30355360

Group type: EXPERIMENTAL
Intervention: Bath emollients plus standard eczema care
Number of subjects: 482

Group type: COMPARATOR
Intervention: Standard eczema care only
Number of subjects: 482
Study: 27058908

Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 8966

Group type: COMPARATOR
Intervention: Stress Testing
Number of subjects: 8966
Study: 23995830

Group type: EXPERIMENTAL
Intervention: Self-Efficacy Scale (SES)
Number of subjects: 47
Study: 23212500

Group type: EXPERIMENTAL
Intervention: Good trainee performances
Number of subjects: 41

Group type: COMPARATOR
Intervention: Poor trainee performances
Number of subjects: 41
Study: 20216274

Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18657672

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d for 3 days before surgery
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Higher postoperative peak N-terminus pro-B-type natriuretic peptide levels
Number of subjects: 124
Study: 15940775

Group type: EXPERIMENTAL
Intervention: 8-week exercise program with strength training and lifestyle advice
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 109
Study: 13678426

Group type: EXPERIMENTAL
Intervention: Self-management of anticoagulation with near patient INR testing monitor, test strips, and quality control material for home testing, after attending at least two training sessions.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard care (control group) attending hospital or practice based anticoagulant clinics.
Number of subjects: 49
Study: 12687426

Group type: EXPERIMENTAL
Intervention: Placement of a supra‐aponeurotic polypropylene mesh in the primary closure of laparotomies (50 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard closure without mesh (50 patients)
Number of subjects: 100
Study: 9794661

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Laser vaporization
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 390
Study: 7697849

Group type: EXPERIMENTAL
Intervention: Early ICD implantation (n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy (n = 31)
Number of subjects: 60